Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients

Open Access

Peer-reviewed

Research Article

Lin L. Liu,

Affiliations Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States of America, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, United States of America
⨯
Fei Li,

Affiliation Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States of America
⨯
William Pao,

Affiliation Vanderbilt-Ingram Cancer Center, Nashville, TN 27232, United States of America
⨯
Franziska Michor

* E-mail: michor@jimmy.harvard.edu

Affiliations Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, United States of America, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, United States of America
⨯

Reader Comments (0)

Carcinogenesis
Is the Subject Area "Carcinogenesis" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Cloning
Is the Subject Area "Cloning" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Dosimetry
Is the Subject Area "Dosimetry" applicable to this article?

Thanks for your feedback.